Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GemBuTT Conditioning with ASCT for CNS Lymphomas
NCT07014943Phase 2Recruiting
- Sponsor
- Sichuan University
- Start
- Jan 2022
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of gemcitabine, busulfan, thiotepa in primary central nervous system lymphoma (PCNSL), sponsored by Sichuan University. Started Jan 2022; status: recruiting.
02
Drugs
gemcitabinebusulfanthiotepa
03
Conditions
primary central nervous system lymphoma (PCNSL)
Beyond the preview
Go deeper on NCT07014943.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07014943.